

### THIS IS TO CERTIFY THAT

# ARROWHEAD REGIONAL MEDICAL CENTER'S PRIMARY CARE CENTERS

## HAS BEEN REVIEWED AND UPDATED AS NEEDED

Die.		8/2/19.
Department Manager		Date
N/A		
Department Chair (if applicable)		Date
Sai Mea		8/2/19
Associate Hospital Administrator (if app	olicable)	Date
V/m K2 mas		8/2/19
Chief Nursing Officer (if applicable)		Date
	-	
Chief Medical Officer (if applicable)		Date
n J. Tellen		8/2/19
Chief Executive Officer		/ Date
Cat Ham	Curt <sup>r</sup> Hagman	AUG 2 0 2019
Chair Board of Supervisors	·	Date

NUAL	Explanation (All New Policies and Major & Minor Revisions)	Policy allows RNs and LVNs with appropriated training to provide the influenza and pneumococcal vaccinations to adult patients with specified criteria, without a physician's order.					
ARROWHEAD REGIONAL MEDICAL CENTER AMBULATORY SERVICES FAMILY HEALTH CENTERS MANUAL August 20. 2019 Summary of Policy Revisions	Policy Title	ADMINISTERING INFLUENZA AND PNEUMOCOCCAL VACCINE TO ADULTS					
ARRC	Reviewed						
AMB	Minor						
	Major						
	New	×					
	Policy #	592.00					



## ARROWHEAD REGIONAL MEDICAL CENTER Primary Care Centers Policies and Procedures

POLICY NO. 592.00 Issue 01 Page 1 of 6

SECTION:	PATIENT CARE	SUB SECTION:	MEDICATIONS
SUBJECT:	ADMINISTERING INFLUEN	ZA & PNEUMOCOCCAL V	ACCINES TO ADULTS
APPROVED BY:	Clinical Director I, An	abulatory Services	

#### **POLICY**

It is the policy of Arrowhead Regional Medical Center to screen, offer and provide the influenza and pneumococcal vaccination to all adult outpatients of clinics and centers that provide primary care, who fit the criteria and do not have any contraindications for the influenza or pneumococcal vaccine. Specialty clinics are to screen, offer and provide the influenza vaccination only.

Under this policy and procedure Registered Nurses (RNs) and Licensed Vocational Nurses (LVNs) with proper training may provide the influenza and pneumococcal vaccinations to patients who fit the criteria below. Federal and State regulations authorize both RNs and LVNs to immunize patients for Influenza and Pneumococcal disease without a physician's order.

#### **PROCEDURES**

#### **INFLUENZA VACCINE**

- I. Assess Adults for Need of Vaccination Against Influenza:
  - A. All adults are recommended to receive influenza each year.
  - B. Women who are or will be pregnant during the influenza season. Administer any recommended, age appropriate inactivated influenza (IIV) or recombinant influenza (RIV) to pregnant women in any trimester.
  - C. People who do not recall whether they received influenza vaccine this year should be vaccinated.
  - D. If there is a flu vaccine shortage, prioritize these groups of people:
    - 1. Chronic lung disease, including asthma
    - 2. Chronic heart or kidney disease
    - 3. Diabetes or other metabolic diseases
    - 4. Immunosuppression (HIV or medications)
    - 5. Hematologic disorders
    - 6. Diseases impacting breathing or creating a risk of aspiration (seizure disorder, neuromuscular disorders, spinal cord injury, sever cognitive disorders).
    - 7. Pregnant women (need preservative free flu vaccine).
    - 8. People in close contact with high risk populations including: healthcare workers, caregiver or household member, caretakers of or people living with a child 0-6 years or an adult age 50 years or older.

SUBJECT: ADMINISTERING INFLUENZA & PNEUMOCOCCAL Policy No. 592.00 Issue 1 VACCINES TO ADULTS Page 2 of 9

#### II. Screen for Contraindications and Precautions:

- A. Contraindications for use of all influenza vaccines
  - 1. Do not give influenza vaccine to a patient who has experienced a serious systemic or anaphylactic reaction to a prior dose of any influenza vaccine or to any of its components (except egg).
  - 2. For a list of vaccine components, refer to the manufacturer's package insert.
- B. Contraindications only for use of live attenuated influenza vaccine (LAIV: FluMist, nasal spray):
  - 1. Do not give live attenuated influenza vaccine to a patient who:
    - a. Is pregnant
    - b. Is immunocompromised due to any cause (including immunosuppression caused by medications or HIV infection)
    - c. Is age 50 years or older
    - d. Received influenza antivirals (e.g. amantadine, rimantadine, zanamivir, oseltamivir or peramivir) within the previous 48 hours
    - e. Is a close contact of or who provides care for a severely immunosuppressed person who requires a protective environment.
- C. Precautions for use of all influenza vaccines:
  - 1. Moderate or severe acute illness with or without fever
  - 2. History of Guillain-Barre syndrome within 6 weeks of a previous influenza vaccination.
- D. Precautions for use of LAIV only:
  - 1. Asthma
  - 2. Other chronic medical conditions that might predispose the patient to complications of influenza infection (e.g. other chronic pulmonary, cardiovascular, renal, hepatic, neurologic, hematologic, or metabolic disorders).
- E. Complete Influenza/Pneumococcal Vaccine Consent/Order (Attachment A).
- III. Vaccine Information Statements:
  - A. Provide all patients with a copy of the most current federal Vaccine Information Statement (VIS).
  - B. Provide non-English speaking patients with a copy of the VIS in their native language.
  - C. Vaccine Information Statements can be found at <a href="https://www.immunize.org/vis">www.immunize.org/vis</a>
- IV. Prepare to Administer Vaccine:
  - A. For vaccine that is to be administered intramuscularly, choose the needle gauge, needle length, and injection site according to the following chart:

Gender and weight of patient	Needle gauge	Needle length	Injection site
Female or male less than 130 lbs	22–25	5⁄8*–1"	Deltoid muscle of arm
Female or male 130–152 lbs	22–25	1"	Deltoid muscle of arm
Female 153–200 lbs	22–25	1–1½"	Deltoid muscle of arm
Male 153–260 lbs	22–25	1–1½"	Deltoid muscle of arm
Female 200+ lbs	22–25	1½"	Deltoid muscle of arm
Male 260+ lbs	22–25	1½"	Deltoid muscle of arm

<sup>\*</sup> A 5/8" needle may be used in patients weighing less than 130 lbs (<60 kg) for IM injection in the deltoid muscle only if theskin is stretched tight, the subcutaneous tissue is not bunched, and the injection is made at a 90-degree angle to the skin.

B. For vaccine that is to be administered intranasal, prepare the vaccine according to the directions in the package insert.

#### V. Administer Influenza Vaccine:

A. Administer influenza vaccine according to the criteria and guidance in the table below:

Type of vaccine	Age group	Dose	Route	Instructions*
Inactivated influenza vaccine (IIV)	All ages	0.5 mL	Intramuscular (IM)	Administer vaccine in deltoid muscle.
IIV-high dose	65 years and older	0.5 mL	Intramuscular (IM)	Administer vaccine in deltoid muscle.
Adjuvanted inactivated influenza vaccine (allV)†	65 years and older	0.5 mL	Intramuscular (IM)	Administer vaccine in deltoid muscle.
Cell culture- based IIV (cclIV)	All ages	0.5 mL	Intramuscular (IM)	Administer vaccine in deltoid muscle.
Recombinant influenza vaccine (RIV)	18 years and older	0.5 mL	Intramuscular (IM)	Administer vaccine in deltoid muscle.
Live attenuated influenza vaccine (LAIV)	Healthy, younger than age 50 years (except pregnant women)	0.2 mL (0.1 mL into each nostril)	Intranasal spray (NAS)	Spray half of vaccine into each nostril while the patient is in an upright position.

SUBJECT:

## ADMINISTERING INFLUENZA & PNEUMOCOCCAL VACCINES TO ADULTS

Policy No. 592.00 Issue 1 Page 4 of 9

\* For complete instructions on how to administer vaccines, see "Clinical Nursing Skills & Techniques by Perry & Potter; additional resource: "How to Administer Intramuscular and Intranasal Influenza Vaccines" at <a href="https://www.immunize.org/catg.d/p2024.pdf">www.immunize.org/catg.d/p2024.pdf</a>

† Given unknown but theoretical concerns of increased reactogenicity when administering two novel adjuvant-containing vaccines (i.e., Fluad, Heplisav-B, Shingrix) and the availability of nonadjuvanted influenza vaccine options, selection of a nonadjuvanted influenza vaccine may be considered in situations where influenza vaccine and another vaccine containing a Novel adjuvant are to be administered concomitantly. However, vaccination should not be delayed if a specific product is not available.

#### PNUEMOCOCCAL VACCINE

- I. Assess Adults for Need of Vaccination against Streptococcus Pneumoniae (pneumococcus) infection.
  - A. Routine pneumococcal vaccination:
    - 1. Assess adults age 65 years or older for need of pneumococcal vaccination.
    - 2. Pneumococcal conjugate vaccine (PCV13) should be administered routinely to all previously unvaccinated adults age 65 years or older.
    - 3. Pneumococcal polysaccharide vaccine (PPSV23) is recommended for all adults age 65 years or older
    - 4. Refer to section 5 of this policy for complete details.
  - B. Risk-based pneumococcal vaccination:
    - 1. Age 19 through 64 years with an underlying medical condition or other risk factor as described in the following table:

CATEGORY OF UNDERLYING	RECOMMENDED VACCINES ARE MARKED "X" BELOW			
MEDICAL CONDITION OR OTHER RISK FACTOR	PCV 13	PPSV23	PPSV23 Booster*	
Chronic heart disease1, Chronic lung disease2		X		
Diabetes mellitus		X		
Chronic liver disease, cirrhosis		X		
Cigarette smoking		X		
Alcoholism		X		
Cochlear implant, cerebrospinal fluid leak	X	X		
Sickle cell disease, other hemoglobinopathy	X	X	X	
Congenital or acquired asplenia	X	X	Х	
Congenital or acquired immuodeficiency3, HIV	Х	Х	X	
Chronic renal failure, nephrotic syndrome	Х	Х	X	
Leukemia, lymphoma	Χ	X	X	
Generalized malignancy, Hodgkin	X	X	Χ	

SUBJECT:

ADMINISTERING INFLUENZA & PNEUMOCOCCAL Policy No. 592.00 Issue 1 VACCINES TO ADULTS Page 5 of 9

disease			1 ago o
latrogenic immunosuppression4	Х	X	X
Solid Organ transplant, multiple			
myeloma	X	X	X

<sup>\*</sup> A second dose 5 years after the first dose of PPSV23, 1 Excluding hypertension; 2 Including asthma; 3 Including B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease); 4 Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy.

#### II. Screen for Contraindications and Precautions:

#### A. Contraindications:

- 1. Do not give pneumococcal vaccine (PCV13 or PPSV23) to a patient who has experienced a serious systemic or anaphylactic reaction to a prior dose of the vaccine or to any of its components.
- 2. For a list of vaccine components, refer to the manufacturer's package insert.

#### B. Precautions:

1. Moderate or severe acute illness with or without fever.

#### III. Provide Vaccine Information Statements:

- A. Provide all patients with a copy of the most current federal Vaccine Information Statement
- B. Provide non-English speaking patients with a copy of the VIS in their native language.
- C. Vaccine Information Statements can be found at www.immunize.org/vis.

#### IV. Prepare to Administer Vaccine:

- A. PCV 13 must be given intramuscularly (IM).
- B. PPSV23 may be administered either IM or subcutaneously
- C. For Vaccine that is to be administered IM, choose the needle gauge, needle length, and injection site according to the following chart:
- D. If you prefer subcutaneous injection of PPSV23, choose a 23-25 gauge, 5/8" needle for injection into the fatty tissue overlying the triceps muscle.

Gender and weight of patient	Needle gauge	Needle length	Injed	tion Site	
Female or male less than 130 lbs	22-25	5/8" * - 1"	Deltoid arm	muscle	of
Female or male 130 – 152 lbs	22-25	1"	Deltoid arm	muscle	of
Female 153 200 lbs	22-25	1-1 ½"	Deltoid arm	muscle	of
Male 153 -260 lbs	22-25	1-1 ½"	Deltoid arm	muscle	of
Female 200+ lbs	22-25	1 ½"	Deltoid arm	muscle	of
Male 260+ lbs	22-25	1 ½"	Deltoid	muscle	of

SUBJECT: ADMINISTERING INFLUENZA & PNEUMOCOCCAL Policy No. 592.00 Issue 1 VACCINES TO ADULTS Page 6 of 9

#### V. Administer PCV13 or PPSV23:

- A. Administer PCV13 or PPSV23 0.5ml according to the following dosing information and schedule:
  - 1. PCV 13 must be administered by the IM route
  - 2. PPSV23 may be administered either IM or Subcutaneous
- B. Routine Vaccination for all adults ages 65 years and older:

AGE OF PATIENT	VACCINE INDICATED	HISTORY OF PRIOR VACCINATION	SCHEDULE FOR ADMINISTRATION OF PCV13 & PPSV23
		None or unknown	Administer PCV13 followed in 1 year* by PPSV23
		PPSV23 when younger than age 65 years; 0 or unknown PCV13	Administer PCV13 at least 1 year after previous PPSV23. Administer another PPSV23 at least 5 years after previous dose of PPSV23 and at least 1 year* after PCV13.
65 yrs or older	PPSV23 and 1 time dose of PCV13	PPSV23 when younger than age 65 years; PCV13	Administer another PPSV23 at least 5 years after previous dose of PPSV23 and at least 1 year* after previous dose of PCV13.
		PPSV23 when age 65 years or older; 0 or unknown PCV13	Administer PCV13 at least 1 year after PPSV23
		0 or unknown PPSV23; PCV13	Administer PPSV23 at least 1 year* after PCV13.

<sup>\*</sup> For adults age 65 years and older with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants, the interval between PCV13 and PPSV23 should be shortened to 8 weeks.

C. Risk-based vaccination for adults ages 19-64 years:

AGE OF PATIENT	VACCINE INDICATED	HISTORY OF PRIOR VACCINATION	SCHEDULE FOR ADMINISTRATION OF PCV13 & PPSV23
40.04	For medical	conditions in which	only PPSV23 is indicated
19-64 Years	1 dose of PPSV23	None or unknown	Administer PPSV23
i cais	For medical c	onditions in which b	oth PCV13 and PPSV23 (1 or 2 doses) are

<sup>\*</sup> A ½" needle may be used in patients weighing less than 130 lbs (<60 kg) for IM injection in the deltoid muscle only if the skin is stretched tight, the subcutaneous tissue is not bunched, and the injection is made at a 90° angle to the skin.

2)	VACCINES TO AL	JULIS	Page / of 9
		reco	mmended
	1 dose PCV13 and	None or unknown	Administer PCV13 followed in 8 weeks bv PPSV23
	1 dose PPSV23 (i.e. cochlear	0 or unknown PPSV23; 1 dose PCV13	Administer PPSV23 at least 8 weeks after PCV13
	implant; CSF leak)	1 dose PPSV23; 0 or unknown PCV13	Administer PCV13 at least 1 year after PPSV23.
		None or unknown	Administer PCV13 followed in 8 weeks by PPSV23 #1. Administer PPSV23 #2 at least 5 years after PPSV23 #1.
I	1 dose PCV13 and 2 doses PPSV23	1 dose PPSV23; 0 or unknown PCV13	Administer PCV13 at least 1 year after PPSV23 #1. Administer PPSV23 #2 at least 5 years after PPSV23 #1 and at least 8 weeks after PCV13
	(i.e. immuno- compromised)	0 or unknown PPSV23; 1 dose PCV13	Administer PPSV23 #1 at least 8 weeks after PCV13. Administer PPSV23 #2 at least 5 years after PPSV23 #1
		1 dose PPSV23; 1 dose PCV13	Administer PPSV23 #2 at least 5 years after PPSV23 #1 and at least 8 weeks after PCV13.
		2 doses PPSV23; 0 or unknown PCV13	Administer PCV13 at least 1 year after PPSV23 #2.

#### **DOCUMENTATION OF VACCINES**

- I. Document Vaccination:
  - A. Document each patients vaccine administration information and follow up in the patient's Medical Record: record the date the vaccine was administered, the manufacturer, lot number, expiration date, the vaccine site and route, publication date of the VIS
  - B. Medical records should be retained in accordance with applicable state laws and regulations.
  - C. If vaccine was not administered, record the reasons for non-receipt of the vaccine (e.g. medical contraindication, patient refusal).
  - D. RN to place influenza and/or pneumococcal vaccine order in PWM for physician to sign off
- II. Physician may cancel influenza and pneumococcal vaccine administration:
  - A. Physician to document in patient's medical record, influenza and/or pneumococcal vaccine not to be administered to patient.

#### **MEDICAL EMERGENCIES**

- I. Be Prepared to Manage Medical Emergencies:
  - A. Be prepared for management of a medical emergency related to the administration of influenza and pneumococcal vaccine by following emergency protocol within the clinic.

SUBJECT: ADMINISTERING INFLUENZA & PNEUMOCOCCAL VACCINES TO ADULTS

Policy No. 592.00 Issue 1 Page 8 of 9

B. To prevent syncope, vaccinate patients while they are seated or lying down.

C. Observe patient for 15 minutes after receipt of the vaccine.

#### **ADVERSE EVENTS**

- I. Report all Adverse Events to Vaccine Adverse Event Reporting System (VAERS):
  - A. Report all adverse events following the administration of influenza and pneumococcal vaccine to the VAERS. To submit a VAERS report online or to download a PDF form, go to <a href="https://vaers.hhs.gov/reportevent.html">https://vaers.hhs.gov/reportevent.html</a>. Further assistance is available at (800) 822-7967.
  - B. Notify Physician immediately of vaccine adverse reaction
  - C. Complete Adverse Drug Reaction Notification using Unusual Occurrence Reporting link found on ARMC Intranet
  - D. Refer to ARMC Department of Pharmacy Services Policy No. 10.1 for complete instructions on reporting and documenting adverse vaccine reactions.

#### STAFF EDUCATION/COMPETENCY

- I. Staff Education and Competency Requirements:
  - A. RN's are qualified to screen and administer the influenza and pneumococcal vaccine upon successful completion of a post-test upon hire and on an annual basis.
  - B. LVN's are qualified to administer the influenza and pneumococcal vaccine upon successful completion of a post-test upon hire and on an annual basis.
  - C. Post tests are maintained in the employee file and in the Education Development Department

REFERENCES: C

Clinical Nursing Skills & Techniques by Perry & Potter

https://www.cdc.gov/flu/professionals/vaccination/index.htm https://www.cdc.gov/vaccines/vpd/pneumo/hcp/index.html

(2018) Use of Standing Orders Programs to Increase Adult Vaccination Rates.

Retrieved July 29, 2019 from the Center for Disease Control Website:

https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4901a2.htm?c cid=journal searc

h promotion 2018

**DEFINITIONS:** 

N/A

**ATTACHMENTS:** 

Influenza/Pneumococcal Vaccine Screening/Consent (English/Spanish)

SUBJECT:

ADMINISTERING INFLUENZA & PNEUMOCOCCAL

VACCINES TO ADULTS

Policy No. 592.00 Issue 1 Page 9 of 9

APPROVAL DATE:

N/A Policy, Procedure and Standards Committee

Nanette Buenavidez, Interim Chief Nursing

7/31/19 Officer Applicable Administrator, Hospital or Medical

Committee

7/31/19 **Pharmacy and Therapeutics Committee** 

Applicable Administrator, Hospital or Medical

Committee

8/1/19 **Quality Management Committee** 

Applicable Administrator, Hospital or Medical

Committee

**Medical Executive Committee** 8/1/19

Applicable Administrator, Hospital or Medical

Committee

8/20/19 **Board of Supervisors** 

Approved by the Governing Body

REPLACES:

N/A

**EFFECTIVE**:

8/20/19

REVISED:

7/31/19

**REVIEWED:** 

7/31/19

### ATTACHMENT A INFLUENZA/PNEUMOCOCCAL VACCINE CONSENT/ORDER

Administer vaccine if ANY of the following boxes are checked:    I am 65 years or older and have never received the vaccine   I influenza vaccine is out of stock at this time   I influenza vaccine is out of stock at this time   I it is not influenza season (October thru March)
□ I was vaccinated before the age of 65 and it has been more than 5 years since I received the pneumococcal vaccine □ I am 19 to 64 years of age and smoke or have asthma and have  If neither of the above choices apply, proceed to the questions below:
years since I received the pneumococcal vaccine  I am 19 to 64 years of age and smoke or have asthma and have  If neither of the above choices apply, proceed to the questions below:
never been vaccinated  ☐ For Females: Are you currently pregnant? If yes, preservative ☐ I am immunocompromised (**see below**) and it has been more ☐ I am immunocompromised (**see below**) and it has been more
than 5 years since I received the pneumococcal vaccine
☐ I am 18 to 64 years of age with any of the following conditions:  Administer vaccine only if ALL boxes are checked:
Immunocompetent persons
Heart disease/CHF/HTN Lung disease/COPD ☐ I have not had a serious reaction/problem with the flu vaccine the past and/or despite my allergies (it in y) want to receive the
DlabetesAlcoholism the past and/or despite my altergies (it my) want to receive the
Liver DiseaseCochlear implant Influenza vaccine
Cerebral Spinal Fluid leak.
**Immunocompromised persons**
Kidney failure/ESRDLymphoma or leukemia
Multiple myeloma Nephrotic syndrome Hodgkin's disease HIV infection or AIDS History of solid organ transplant History of solid organ transplant
Hodgkin's classes History of any egg allerg. Knowing this fact and risks, I choose to history of any egg allerg. Knowing this fact and risks, I choose to history of any egg allerg. Knowing this fact and risks, I choose to
History of solid organ transplant  Medication that affects my immune system (Long-term steroid use or radiation/cancer treatment more than 2 weeks ago)  History of solid organ transplant  Center; its employeed and epiesentatives from any liability or further responsibility with legal 1 fr my receiving the vaccine.
use or radiation/cancer treatment more than 2 weeks ago) responsibility will happen to my receiving the vaccine
Asplenia (sickle cell disease, malposition of the heart,
anomalies of the spleen)
EXCLUSION CRITERIA: Do not give influenza vaccine if ANY box EXCLUSION CRITERIA: Do not give influenza vaccine if ANY box is
s checked below: checked below:
If patient is less than 18 years of age (Physician order required)
☐ I am pregnant (Reassess the need for pneumococcal vaccination if the baby is delivered during this hospitalization)  The baby is delivered during this hospitalization)
☐ Documentation of: ☐ Allergy/sensitivity to influenza vaccine or anaphylactic allergy to
Pneumococcal vaccine given this hospitalization or in negatilatex or Thirmerosal
Bone marrow transplant within the past 12 months
Receiving chemotherapy or radiation therapy define this hospitalization or within 2 weeks after a previous influenza vaccination
Received Zostavax (Shingle's vaccine) within it lest 4 weeks D Patients with an organ transplant during the current hospitalization
Patients with an organ transplant during the clarest hospitalization  ☐ Patient declined
Allergy/sensitivity to preumococcat vaccine
Palient declined
☐ Current Pneumococcal Vaccine Information Statement (04/24/15) given to patient/representative.
☐ Current Influenza Vaccine Information Statement (08/07/15) given to patient/representative.
SCREENED BY:  PRINT NAME SIGNATURE TITLE DATE TIME
CONSENT (Place a check hark in the box(s) below to indicate the type of vaccine you are giving consent to receive)
I choose to accept the: D Pneumococcal Vaccine II Influenza (Flu) Vaccine
I am signing this egneent to verify that I have not had a serious reaction or problem with the vaccine(s) in the past. I have read or had explained to r
the information stort the vaccine(s) and have had all of my questions answered. I understand the risks and benefits of the vaccine and authorize it be given to me.
SIGNATURE OF PATIENT CHAUTHCHIZED REPRESENTATIVE RELATIONS > FOTHER THAN PATIENT SONATURE DATE
VACCINE'S NOT GIVEN FOR THE FOLLOWING REASONS:   ☐ Any of the exclusion criteria checked  ☐ Patient declined
I choose to decline the
SIGNATURE OF PATIENT OR AUTHORIZED REPRESENTATIVE RELATIONSHIP IF OTHER THAN PATIENT SIGNATURE DATE

TO OBTAIN VACCINE(S) PLEASE SCAN OR SEND THIS FORM TO THE PHARMACY

PATIENT IDENTIFICATION

ARROWHEAD REGIONAL MEDICAL CENTER

INFLUENZA/PNEUMOCOCCAL VACCINE CONSENT/ORDER

